Ludger Kolbe

Dr. Ludger Kolbe

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
TMTobias Mann
Tobias Mann
WGWolfram Gerwat
Wolfram Gerwat
JBJan Batzer
Jan Batzer
KEKerstin Eggers
Kerstin Eggers
CSCathrin Scherner
Cathrin Scherner
LKLudger Kolbe
Ludger Kolbe
Tyrosinase is the rate-limiting enzyme of melanin production and, accordingly, is the most prominent target for inhibiting hyperpigmentation. Numerous tyrosinase inhibitors have been identified, but most of those lack clinical efficacy because they were identified using mushroom tyrosinase as the target. Therefore, we used recombinant human tyrosinase to screen a library of 50,000 compounds and compared the active screening hits with well-known whitening ingredients. Hydroquinone and its derivative arbutin only weakly inhibited human tyrosinase with a half-maximal inhibitory concentration (IC50) in the millimolar range, and kojic acid showed a weak efficacy (IC50 > 500 μmol/L). The most potent inhibitors of human tyrosinase identified in this screen were resorcinyl-thiazole derivatives, especially the newly identified Thiamidol (Beiersdorf AG, Hamburg, Germany) (isobutylamido thiazolyl resorcinol), which had an IC50 of 1.1 μmol/L. In contrast, Thiamidol only weakly inhibited mushroom tyrosinase (IC50 = 108 μmol/L). In melanocyte cultures, Thiamidol strongly but reversibly inhibited melanin production (IC50 = 0.9 μmol/L), whereas hydroquinone irreversibly inhibited melanogenesis (IC50 = 16.3 μmol/L). Clinically, Thiamidol visibly reduced the appearance of age spots within 4 weeks, and after 12 weeks some age spots were indistinguishable from the normal adjacent skin. The full potential of Thiamidol to reduce hyperpigmentation of human skin needs to be explored in future studies.

3 December 2012 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
LKLudger Kolbe
Ludger Kolbe
TMT. Mann
T. Mann
WGW. Gerwat
W. Gerwat
JBJ. Batzer
J. Batzer
SAS. Ahlheit
S. Ahlheit
FSF. Stäb
F. Stäb
Background  Hyperpigmentary disorders like melasma, actinic and senile lentigines are a major cosmetic concern. Therefore, many topical products are available, containing various active ingredients aiming to reduce melanin production and distribution. The most prominent target for inhibitors of hyperpigmentation is tyrosinase, the key regulator of melanin production. Many inhibitors of tyrosinase are described in the literature; however, most of them lack clinical efficacy.Methods  We were interested in evaluating the inhibition of skin pigmentation by well‐known compounds with skin‐whitening activity like hydroquinone, arbutin, kojic acid and 4‐n‐butylresorcinol. We compared the inhibition of human tyrosinase activity in a biochemical assay as well as inhibition of melanin production in MelanoDerm™ skin model culture. For some compounds, the in vivo efficacy was tested in clinical studies.Results  Arbutin and hydroquinone only weakly inhibit human tyrosinase with a half maximal inhibitory concentration (IC50) in the millimolar range. Kojic acid is 10 times more potent with an IC50 of approximately 500 μmol/L. However, by far the most potent inhibitor of human tyrosinase is 4‐n‐butylresorcinol with an IC50 of 21 μmol/L. In artificial skin models, arbutin was least active with an IC50 for inhibition of melanin production > 5000 μmol/L. Kojic acid inhibited with an IC50 > 400 μmol/L. Interestingly, hydroquinone inhibited melanin production in MelanoDerms with an IC50 below 40 μmol/L, probably due to a mechanism different from tyrosinase inhibition. Again, 4‐n‐butylresorcinol was the most potent inhibitor with an IC50 of 13.5 μmol/L. In vivo efficacy of 4‐n‐butyl‐resorcinol was confirmed in clinical studies. Subjects with age spots on the forearm treated twice daily two age spots with a formula containing 4‐n‐butylresorcinol and two control age spots with the corresponding vehicle. Within 8 weeks, 4‐n‐butylresorcinol reduced visibly the appearance of age spots, while the control spots showed no improvement. A second study showed that 4‐butylresorcinol was more effective than 4‐hexylresorcinol and 4‐phenylethylresorcinol.Conclusion  The present in vitro and in vivo data prove the high inhibitory capacity of 4‐n‐butylresorcinol on human tyrosinase activity, exceeding by far the potency of hydroquinone, arbutin and kojic acid. The resulting clinical improvement of skin hyperpigmentations reveals 4‐n‐butylresorcinol as a very valuable active compound for the management of pigmentation disorders.

22 March 2006 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
LKLudger Kolbe
Ludger Kolbe
JIJeannine Immeyer
Jeannine Immeyer
JBJan Batzer
Jan Batzer
UWUrsula Wensorra
Ursula Wensorra
KDKaren Tom Dieck
Karen Tom Dieck
HWHorst Wenck
Horst Wenck

1 August 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
CACraig Arrowitz
Craig Arrowitz
ASAndrea M. Schoelermann
Andrea M. Schoelermann
TMTobias Mann
Tobias Mann
LJLily I. Jiang
Lily I. Jiang
TWTeresa Weber
Teresa Weber
LKLudger Kolbe
Ludger Kolbe
Melasma is a pigmentary disorder characterized by hyperpigmented patchy skin in sun-exposed areas, especially the face. Treatment of melasma can be challenging because long-term therapy is required, reoccurrence is common, and existing therapies are insufficient and unsatisfactory. To investigate new treatment options, we performed an exploratory double-blinded, randomized split-face study to assess the efficacy of the tyrosinase inhibitor Thiamidol compared to hydroquinone in women with mild to moderate melasma. After 12 weeks, modified Melasma Area and Severity Index scores significantly improved on both the Thiamidol-treated and the hydroquinone-treated sides of the face. Additionally, Thiamidol treatment improved modified Melasma Area and Severity Index scores significantly better than hydroquinone, and more subjects improved following treatment with Thiamidol (79%) compared with hydroquinone (61%). During treatment, no subjects displayed worsening of modified Melasma Area and Severity Index scores on the Thiamidol-treated side, while approximately 10% of the subjects showed a worsening of modified Melasma Area and Severity Index scores on the hydroquinone-treated side. All subjects routinely used sunscreens and consistent results were obtained in low and in high UV ambient conditions. Subjects rated the efficacy of the Thiamidol formulation significantly better with regard to overall decreased intensity of dark spots and their overall appearance throughout the study. Thiamidol was well-tolerated and well-perceived and represents an effective agent to reduce hyperpigmentation.

29 October 2019 in Photodermatology, Photoimmunology & Photomedicine
Verified
Journal Article
Open access
PDF file
TMTobias Mann
Tobias Mann
KEKerstin Eggers
Kerstin Eggers
FRFrank Rippke
Frank Rippke
MTMirko Tesch
Mirko Tesch
ABAnette Buerger
Anette Buerger
LKLudger Kolbe
Ludger Kolbe
Background: Solar radiation causes skin damage through the generation of reactive oxygen species (ROS). While UV filters effectively reduce UV‐induced ROS, they cannot prevent VIS‐induced (400‐760 nm) oxidative stress. Therefore, potent antioxidants are needed as additives to sunscreen products.Methods: We investigated VIS‐induced ROS formation and the photoprotective effects of the Nrf2 inducer Licochalcone A (LicA).Results: Visible spectrum of 400‐500 nm dose‐dependently induced ROS in cultured human fibroblasts at doses equivalent to 1 hour of sunshine on a sunny summer day (150 J/cm2). A pretreatment for 24 hours with 1 µmol/L LicA reduced ROS formation to the level of unirradiated cells while UV filters alone were ineffective, even at SPF50+. In vivo, topical treatment with a LicA‐containing SPF50 + formulation significantly prevented the depletion of intradermal carotenoids by VIS irradiation while SPF50 + control did not protect.Conclusion: LicA may be a useful additive antioxidant for sunscreens.

13 September 2016 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
WCWonseon Choi
Wonseon Choi
LYLanlan Yin
Lanlan Yin
CSChristoph Smuda
Christoph Smuda
JBJan Batzer
Jan Batzer
VHVincent J. Hearing
Vincent J. Hearing
LKLudger Kolbe
Ludger Kolbe